Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria X Wang, Santiago Garcia, PhD, Laura Ann Bruins, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 4373.

https://doi.org/10.1182/blood.V128.22.4373.4373

Published: 2016

Journal Articles

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Tania Jain, M.B.,B.S, Shu Ting Kung, MD, Vishal Shah, Pharm.D., R.Ph., Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, P. Leif Bergsagel, MD, Craig B. Reeder, MD, Pierre Noel, MD, Roberta H. Adams, MD, Susan Luft, M.S., R.N., Angela Mayo, P.A.-C., M.S., A. Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4629.

https://doi.org/10.1182/blood.V128.22.4629.4629

Published: 2016

Journal Articles

Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database

Aneel Paulus, MD, Mayank Sharma, MBBS, Shumail M. Paulus, MBBS, Richa Menghani, MD, Elisa M. Rodriguez, Ryan D Frank, MS, George Cooper, David Hodge, Vivek Roy, MD, Rafael Fonseca, MD, Asher A. Chanan-Khan, MD, Peter Leif Bergsagel, MD, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 4432.

https://doi.org/10.1182/blood.V128.22.4432.4432

Published: 2016

Journal Articles

Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma

Tania Jain, M.B.,B.S, Hemalatha Narayanasamy, M.B.B.S., Joseph Mikhael, MD, Craig B. Reeder, MD, P. Leif Bergsagel, MD, Angela Mayo, P.A.-C., M.S., A. Keith Stewart, MBChB, Farouk Mookadam, M.B., B.Ch., Rafael Fonseca, MD

Blood (2016) 128 (22): 2126.

https://doi.org/10.1182/blood.V128.22.2126.2126

Published: 2016

Journal Articles

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Blood (2016) 128 (22): 491.

https://doi.org/10.1182/blood.V128.22.491.491

Published: 2016

Journal Articles

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Sinto Sebastian Chirackal, PhD, Esteban Braggio, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Scott Van Wier, Gregory Ahmann, Veronica Gonzalez-Calle, MD, Marta Chesi, PhD, Leif Bergsagel, MD, Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4482.

https://doi.org/10.1182/blood.V128.22.4482.4482

Published: 2016

Journal Articles

Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients

Veronica Gonzalez-Calle, MD, Abigail Slack, Susan Luft, M.S., R.N., Kathryn Pearce, Rhett P. Ketterling, MD, Tania Jain, M.B., B.S, Sinto Sebastian Chirackal, PhD, Craig B. Reeder, MD, Joseph Mikhael, MD, Leif Bergsagel, MD, Pierre Noel, MD, Angela Mayo, P.A.-C., M.S., James L. Slack, MD, Roberta H. Adams, MD, Gregory Ahmann, Esteban Braggio, PhD, Keith Stewart, M.B., Ch.B., Scott Van Wier, Rafael Fonseca, MD

Blood (2016) 128 (22): 3452.

https://doi.org/10.1182/blood.V128.22.3452.3452

Published: 2016

NARROW

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database

Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database

Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only